Company Cash Funds: Windtree (WINT)

Windtree Therapeutics specializes in critical heart condition therapies, where the success of istaroxime and Fast Track status serve as the primary catalysts. Cash and cash equivalents in the GURU.Markets system provide current liquidity dynamics, with the current figure standing at 0.00. Growth potential is based on the patent protection of molecules, while pricing power will only emerge following the completion of final tests.
Summary analytical data breakdowns for Windtree Therapeutics, Inc. (WINT)

This indicator is calculated as the aggregate value of liquid assets, adjusted for reporting time lags. The metric determines the issuer's actual survival horizon before a cash gap occurs in the absence of inflows. For Windtree Therapeutics (WINT), this reserve is critical for maintaining the uninterrupted express delivery of cardiology drugs. The current value of 0.00 reflects the financial stability of operational logistics. The dynamics of cash on the balance sheet allow for a real-time assessment of the risk of supply disruptions in intensive care units.